These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22180252)

  • 41. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated meta-analysis.
    Xu HB; Zhang H; Qin Y; Xue F; Xiong G; Yang L; Bai H; Wu J
    J Neurol Sci; 2018 Jul; 390():139-149. PubMed ID: 29801875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Michel P
    Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced Stroke After Transcatheter Patent Foramen Ovale Closure: A Systematic Review and Meta-analysis.
    Alvarez C; Siddiqui WJ; Aggarwal S; Hasni SF; Hankins S; Eisen H
    Am J Med Sci; 2018 Aug; 356(2):103-113. PubMed ID: 30219151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke.
    Smer A; Salih M; Mahfood Haddad T; Guddeti R; Saadi A; Saurav A; Belbase R; Ayan M; Traina M; Alla V; Del Core M
    Am J Cardiol; 2018 Jun; 121(11):1393-1399. PubMed ID: 29680170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data.
    Hakeem A; Cilingiroglu M; Katramados A; Boudoulas KD; Iliescu C; Gundogdu B; Marmagkiolis K
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1153-1160. PubMed ID: 29332308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
    Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
    Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cryptogenic Strokes and Patent Foramen Ovales: What's the Right Treatment?
    Dalen JE; Alpert JS
    Am J Med; 2016 Nov; 129(11):1159-1162. PubMed ID: 27566504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.
    Kent DM; Dahabreh IJ; Ruthazer R; Furlan AJ; Weimar C; Serena J; Meier B; Mattle HP; Di Angelantonio E; Paciaroni M; Schuchlenz H; Homma S; Lutz JS; Thaler DE
    Eur Heart J; 2015 Sep; 36(35):2381-9. PubMed ID: 26141397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
    Sagris D; Georgiopoulos G; Perlepe K; Pateras K; Korompoki E; Makaritsis K; Vemmos K; Milionis H; Ntaios G
    Stroke; 2019 Nov; 50(11):3135-3140. PubMed ID: 31547797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Closure of Patent Foramen Ovale and Cryptogenic Stroke: Unresolved Issues.
    Diener HC; Gerloff C; Thaler DE; Wöhrle J
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):92. PubMed ID: 30328522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device.
    Varotto L; Bregolin G; Paccanaro M; De Boni A; Bonanno C; Perini F
    Cerebrovasc Dis; 2020; 49(2):124-134. PubMed ID: 32289794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design.
    Khattab AA; Windecker S; Jüni P; Hildick-Smith D; Dudek D; Andersen HR; Ibrahim R; Schuler G; Walton AS; Wahl A; Mattle HP; Meier B
    Trials; 2011 Feb; 12():56. PubMed ID: 21356042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials.
    Hakeem A; Marmagkiolis K; Hacioglu Y; Uretsky BF; Gundogdu B; Leesar M; Bailey SR; Cilingiroglu M
    Cardiovasc Revasc Med; 2013; 14(6):349-55. PubMed ID: 24080379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
    Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
    Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials.
    Niu X; Ou-Yang G; Yan PF; Huang SL; Zhang ZT; Zhang ZH
    J Neurol; 2018 Jun; 265(6):1259-1268. PubMed ID: 29383514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale.
    Casaubon L; McLaughlin P; Webb G; Yeo E; Merker D; Jaigobin C
    Can J Neurol Sci; 2007 Feb; 34(1):74-80. PubMed ID: 17352351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.